Patents by Inventor Mark Von Itzstein
Mark Von Itzstein has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240109886Abstract: The present invention relates to a compound of Formula (I), or a pharmaceutically acceptable salt thereof, and to pharmaceutical compositions comprising the compound. In Formula (I), rings W, X, Y and Z may relate to various heterocyclic, heteroaryl, cycloalkyl, cycloalkenyl, and/or aryl rings. The present invention also relates to uses of the compounds in treating a disease, disorder or condition caused by viral infection.Type: ApplicationFiled: January 28, 2022Publication date: April 4, 2024Applicant: GRIFFITH UNIVERSITYInventors: Mark VON ITZSTEIN, Ibrahim EL-DEEB, Patrice GUILLON, Larissa HEILIG
-
Publication number: 20230255992Abstract: The present invention relates to compounds with high chemical stability and methods for inhibiting the pathological activity of extracellular histones in a subject. In particular, the invention relates to compounds with high chemical stability, uses thereof and methods for inhibiting or ameliorating extracellular histone mediated ailments (such as, for example, sepsis, systemic immune response syndrome (SIRS) and ischemia reperfusion injury (IRO). More particularly, the invention relates to methods and uses of a polyanionic sulfated cellobioside modified with a small uncharged glycosidically linked substituent at its reducing terminus, wherein the presence of the substituent results in a molecule with high chemical stability without affecting the ability of the molecule to be effective in the therapy of extracellular histone mediated ailments. For example, the present invention relates to methods and uses of ?-O-methyl cellobioside sulfate (mCBS) or a pharmaceutically acceptable salt thereof (e.g.Type: ApplicationFiled: February 6, 2023Publication date: August 17, 2023Applicants: The Australian National University, Griffith UniversityInventors: Christopher Parish, Connor O'Meara, Lucy Coupland, Benjamin Ju Chye Quah, Farzaneh Kordbacheh, Anna Orlov, Anna Browne, Ross Stephens, Gregory David Tredwell, Lee Andrew Philip, Karen Knox, Laurence Mark von Itzstein, Chih-Wei Chang, Anne Brüstle, David Anak Simon Davis
-
Patent number: 11628179Abstract: The present invention relates to compounds with high chemical stability and methods for inhibiting the pathological activity of extracellular histones in a subject. In particular, the invention relates to compounds with high chemical stability, uses thereof and methods for inhibiting or ameliorating extracellular histone mediated ailments (such as, for example, sepsis, systemic immune response syndrome (SIRS) and ischemia reperfusion injury (IRI)). More particularly, the invention relates to methods and uses of a polyanionic sulfated cellobioside modified with a small uncharged glycosidically linked substituent at its reducing terminus, wherein the presence of the substituent results in a molecule with high chemical stability without affecting the ability of the molecule to be effective in the therapy of extracellular histone mediated ailments. For example, the present invention relates to methods and uses of ?-O-methyl cellobioside sulfate (mCBS) or a pharmaceutically acceptable salt thereof (e.g., mCBS.Type: GrantFiled: December 14, 2018Date of Patent: April 18, 2023Assignees: The Australian National University, Griffith UniversityInventors: Christopher Parish, Connor O'Meara, Lucy Coupland, Benjamin Ju Chye Quah, Farzaneh Kordbacheh, Anna Orlov, Anna Browne, Ross Stephens, Gregory David Tredwell, Lee Andrew Philip, Karen Knox, Laurence Mark von Itzstein, Chih-Wei Chang, Anne Brüstle, David Anak Simon Davis
-
Publication number: 20220274965Abstract: The present invention relates to a compound of formula (I), or a pharmaceutically acceptable salt thereof: Formula (I) In which R3 is selected from the group consisting of optionally substituted N-linked naphthotriazole, optionally substituted N-linked indazole, and certain N-linked triazoles. The present invention also relates to uses of the compounds in treating a disease, disorder or condition caused by viral infection, and pharmaceutical compositions comprising the compounds.Type: ApplicationFiled: July 30, 2020Publication date: September 1, 2022Applicant: GRIFFITH UNIVERSITYInventors: Mark Von Itzstein, Ibrahim El-Deeb, Larissa Heilig, Patrice Guillon
-
Publication number: 20220168327Abstract: The present invention relates to compounds with high chemical stability and methods for inhibiting the pathological activity of NETs in a subject. In particular, the invention relates to compounds with high chemical stability, uses thereof and methods for inhibiting or ameliorating NET mediated ailments (such as, for example, sepsis, systemic immune response syndrome (SIRS) and ischemia reperfusion injury (IRI)). More particularly, the invention relates to methods and uses of a polyanionic sulfated cellobioside modified with a small uncharged glycosidically linked substituent at its reducing terminus, wherein the presence of the substituent results in a molecule with high chemical stability without affecting the ability of the molecule to be effective in the therapy of NET mediated ailments. For example, the present invention relates to methods and uses of ?-O-methyl cellobioside sulfate (mCBS) or a pharmaceutically acceptable salt thereof (e.g., mCBS.Type: ApplicationFiled: February 25, 2019Publication date: June 2, 2022Inventors: Christopher Parish, Connor O'Meara, Lucy Coupland, Benjamin Ju Chye Quah, Farzaneh Kordbacheh, Anna Bezos, Anna Browne, Ross Stephens, Gregory David Tredwell, Lee Andrew Philip, Karen Knox, Laurence Mark von Itzstein, Chih-Wei Chang, Anne Brüstle, David Anak Simon Davis
-
Publication number: 20210205343Abstract: The present invention relates to compounds with high chemical stability and methods for inhibiting the pathological activity of extracellular histones in a subject. In particular, the invention relates to compounds with high chemical stability, uses thereof and methods for inhibiting or ameliorating extracellular histone mediated ailments (such as, for example, sepsis, systemic immune response syndrome (SIRS) and ischemia reperfusion injury (IRI)). More particularly, the invention relates to methods and uses of a polyanionic sulfated cellobioside modified with a small uncharged glycosidically linked substituent at its reducing terminus, wherein the presence of the substituent results in a molecule with high chemical stability without affecting the ability of the molecule to be effective in the therapy of extracellular histone mediated ailments. For example, the present invention relates to methods and uses of ?-O-methyl cellobioside sulfate (mCBS) or a pharmaceutically acceptable salt thereof (e.g., mCBS.Type: ApplicationFiled: December 14, 2018Publication date: July 8, 2021Inventors: Christopher Parish, Connor O'Meara, Lucy Coupland, Benjamin Ju Chye Quah, Farzaneh Kordbacheh, Anna Bezos, Anna Browne, Ross Stephens, Gregory David Tredwell, Lee Andrew Philip, Karen Knox, Laurence Mark von Itzstein, Chih-Wei Chang, Anne Brüstle, David Anak Simon Davis
-
Publication number: 20200261440Abstract: This invention relates to the use of zinc(II) salts in combination with a zinc ionophore to resensitize a previously resistant pathogenic bacteria to an antibiotic. Methods of restoring the sensitivity of a resistant pathogenic bacterium to an antibiotic comprising administering a zinc ionophore in combination with a zinc(II) salt and methods of treating a bacterial infection comprising administering a zinc ionophore in combination with a zinc (II) salt concurrently and/or sequentially with administration of a therapeutically effective amount of an antibiotic is also described.Type: ApplicationFiled: October 12, 2018Publication date: August 20, 2020Inventors: Mark WALKER, Christopher MCDEVITT, Mark VON ITZSTEIN, Alastair MCEWAN
-
Patent number: 10028938Abstract: The present invention relates to compounds which are found to exhibit an antiviral effect. The compounds are modulators of the activity of the viral haemagglutinin and/or neuraminidase enzymes.Type: GrantFiled: September 7, 2015Date of Patent: July 24, 2018Assignee: Griffith UniversityInventors: Mark Von Itzstein, Ibrahim El-Deeb, Larissa Dirr, Patrice Guillon, Moritz Winger
-
Publication number: 20170290809Abstract: The present invention relates to compounds which are found to exhibit an antiviral effect. The compounds are modulators of the activity of the viral haemagglutinin and/or neuraminidase enzymes.Type: ApplicationFiled: September 7, 2015Publication date: October 12, 2017Applicant: Griffith UniversityInventors: Mark Von Itzstein, Ibrahim El-Deeb, Larissa Dirr, Patrice Guillon, Moritz Winger
-
Publication number: 20120202877Abstract: The present invention relates to compounds that selectively inhibit influenza A virus group (1) sialidases and are therefore potential anti-influenza agents.Type: ApplicationFiled: July 16, 2010Publication date: August 9, 2012Inventors: Mark Von Itzstein, Jeffrey Clifford Dyason, Robin Thomson, Santosh Rudrawar, Mauro Pascolutti
-
Patent number: 5648379Abstract: Derivatives and analogues of 2-deoxy-2,3-didehydro-N-acetyl neuraminic acid, pharmaceutical formulations thereof, methods for their preparation and their use in the treatment of viral infections, in particular influenza, are described.Type: GrantFiled: October 19, 1994Date of Patent: July 15, 1997Assignee: Biota Scientific Management Pty., Ltd.Inventors: Laurence Mark Von Itzstein, Wen-Yang Wu, Tho Van Phan, Basil Danylec, Betty Jin, Peter Malcolm Colman, Joseph Noozhumurry Varghese
-
Patent number: 5639786Abstract: N-Acetylneuraminic and derivatives of formula (I) ##STR1## pharmaceutical formulations thereof, their use in medicine, in particular as antiviral agents and methods for their preparation are described.Type: GrantFiled: June 29, 1994Date of Patent: June 17, 1997Assignee: BIOTA Scientific Management, Pty., Ltd.Inventors: Laurence Mark Von Itzstein, Wen-Yang Wu, Tho Van Phan, Basil Danylec, Betty Jin